Free Trial Information
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

...Tusk Therapeutics Ltd. (Stevenage, U.K.) hired Matthew Hall as CFO. He was CFO at Simbec- Orion Group...
Read More
BioCentury | Mar 5, 2007
Clinical News

BG Medicine preclinical data

...N.Y.), Johnson & Johnson (JNJ, New Brunswick, N.J.), Mitsubishi Chemical Holdings Corp. (Tokyo:4188, Tokyo, Japan), Orion Group...
Read More
BioCentury | Jul 10, 2006
Company News

Orion Group pharmaceuticals, diagnostic news

Orion Group (HSE:ORNAS; HSE:ORNBS), Espoo, Finland Business: Pharmaceuticals, Diagnostic ORNAS split into two publicly held companies: Orion Corp. and Oriola-KD. Orion Corp., which trades under the tickers ORNAV and ORNBV, consists of the Orion Pharma...
Read More
BioCentury | May 22, 2006
Clinical News

Simdax levosimendan: Phase III start

...another (see BioCentury, Nov. 21, 2005). Simdax is marketed outside the U.S. to treat ADHF. Orion Group...
Read More
BioCentury | Nov 21, 2005
Clinical News

Simdax levosimendan: Phase III data

...ex-U.S. as an adjunctive therapy for short-term treatment of acutely decompensated severe chronic heart failure. Orion Group...
Read More
BioCentury | Nov 21, 2005
Clinical News

Simdax levosimendan: Phase III data

...ex-U.S. as an adjunctive therapy for short-term treatment of acutely decompensated severe chronic heart failure. Orion Group...
Read More
BioCentury | Jan 31, 2005
Clinical News

Acapodene Toremifene: Phase III started

...SPA from FDA and plans to resubmit a revised SPA. GTx Inc. (GTXI), Memphis, Tenn. Orion Group...
Read More
BioCentury | Dec 20, 2004
Company News

GTx, Orion Group deal

...to toremifene for men's health indications under a 2000 deal. GTx Inc. (GTXI), Memphis, Tenn. Orion Group...
Read More
BioCentury | Nov 1, 2004
Clinical News

Stalevo levodopa/carbidopa/entacapone: Started Phase III

...III STRIDE-PD trial in about 740 patients comparing Stalevo to a traditional formulation of levodopa/carbidopa. Orion Group...
Read More
BioCentury | Jun 14, 2004
Clinical News

Acapodene toremifene: Phase II data

...the American Society of Clinical Oncology meeting in New Orleans. GTx Inc. (GTXI), Memphis, Tenn. Orion Group...
Read More
Items per page:
1 - 10 of 19
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

...Tusk Therapeutics Ltd. (Stevenage, U.K.) hired Matthew Hall as CFO. He was CFO at Simbec- Orion Group...
Read More
BioCentury | Mar 5, 2007
Clinical News

BG Medicine preclinical data

...N.Y.), Johnson & Johnson (JNJ, New Brunswick, N.J.), Mitsubishi Chemical Holdings Corp. (Tokyo:4188, Tokyo, Japan), Orion Group...
Read More
BioCentury | Jul 10, 2006
Company News

Orion Group pharmaceuticals, diagnostic news

Orion Group (HSE:ORNAS; HSE:ORNBS), Espoo, Finland Business: Pharmaceuticals, Diagnostic ORNAS split into two publicly held companies: Orion Corp. and Oriola-KD. Orion Corp., which trades under the tickers ORNAV and ORNBV, consists of the Orion Pharma...
Read More
BioCentury | May 22, 2006
Clinical News

Simdax levosimendan: Phase III start

...another (see BioCentury, Nov. 21, 2005). Simdax is marketed outside the U.S. to treat ADHF. Orion Group...
Read More
BioCentury | Nov 21, 2005
Clinical News

Simdax levosimendan: Phase III data

...ex-U.S. as an adjunctive therapy for short-term treatment of acutely decompensated severe chronic heart failure. Orion Group...
Read More
BioCentury | Nov 21, 2005
Clinical News

Simdax levosimendan: Phase III data

...ex-U.S. as an adjunctive therapy for short-term treatment of acutely decompensated severe chronic heart failure. Orion Group...
Read More
BioCentury | Jan 31, 2005
Clinical News

Acapodene Toremifene: Phase III started

...SPA from FDA and plans to resubmit a revised SPA. GTx Inc. (GTXI), Memphis, Tenn. Orion Group...
Read More
BioCentury | Dec 20, 2004
Company News

GTx, Orion Group deal

...to toremifene for men's health indications under a 2000 deal. GTx Inc. (GTXI), Memphis, Tenn. Orion Group...
Read More
BioCentury | Nov 1, 2004
Clinical News

Stalevo levodopa/carbidopa/entacapone: Started Phase III

...III STRIDE-PD trial in about 740 patients comparing Stalevo to a traditional formulation of levodopa/carbidopa. Orion Group...
Read More
BioCentury | Jun 14, 2004
Clinical News

Acapodene toremifene: Phase II data

...the American Society of Clinical Oncology meeting in New Orleans. GTx Inc. (GTXI), Memphis, Tenn. Orion Group...
Read More
Items per page:
1 - 10 of 19